focusing on cancer indications with the greatest medical need for new treatments
Featured News & Events
Oct 20, 2020
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
Oct 14, 2020
Dr. Mark Erlander, Cardiff Oncology CEO, Discusses KRAS Mutations in Cancer | Podcast S2 E39
Sep 29, 2020
Cardiff Oncology Prices Public Offering
Our Clinical Programs
Zytiga-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.
KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.